The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

BCMA-Targeted CAR-T Cell Therapy for Multiple Myeloma

Chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen for relapsed/refractory disease

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is BCMA-Targeted CAR-T Cell Therapy for Multiple Myeloma?

Patient T cells are collected through leukapheresis, genetically modified to express anti-BCMA chimeric antigen receptors and infused back to the patient.

BCMA expression on plasma cells provides specific tumor target with limited expression on other tissues.

Approved indications include heavily pretreated relapsed/refractory multiple myeloma after multiple prior therapies.

Lymphodepleting chemotherapy with fludarabine and cyclophosphamide precedes CAR-T cell infusion to optimize engraftment.

Cells expand and persist in vivo providing prolonged antitumor activity though duration varies between products and patients.

Symptoms

Cytokine release syndrome occurs commonly with fever, hypotension, hypoxia and organ dysfunction requiring tocilizumab and corticosteroids.
Immune effector cell-associated neurotoxicity syndrome (ICANS) presents with confusion, encephalopathy, seizures and rarely cerebral edema.
Cytopenias including prolonged neutropenia, anemia and thrombocytopenia require supportive care and growth factor support.
Infections particularly opportunistic infections occur due to lymphodepletion and B-cell aplasia requiring antimicrobial prophylaxis.
Hypogammaglobulinemia commonly develops requiring immunoglobulin replacement therapy.

Risk Factors

High disease burden at apheresis time may increase cytokine release syndrome severity.
Performance status and organ function affect tolerability of intensive treatment.
Prior allogeneic stem cell transplant or extensive prior therapy affects T-cell quality and engraftment.
Active infection requires evaluation and treatment before CAR-T cell administration.
Cardiac, pulmonary or renal dysfunction limits ability to tolerate cytokine release syndrome.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Fever, hypotension, dyspnea or other systemic symptoms during CAR-T cell therapy require immediate hospital evaluation.
  • Confusion, headache, weakness or seizures require urgent neurologic evaluation for ICANS.
  • Bleeding, easy bruising or signs of infection require evaluation for cytopenias and possible transfusion or antimicrobial therapy.
  • Persistent fatigue or new symptoms after discharge require oncologic evaluation given prolonged immunosuppression.
  • Severe complications require intensive care management with multidisciplinary team.

Treatment Methods

01
Comprehensive pretreatment evaluation including disease burden assessment, organ function, infection screening and performance status.
02
Lymphodepleting chemotherapy followed by CAR-T cell infusion in specialized inpatient or outpatient setting per protocol.
03
Vigilant monitoring for cytokine release syndrome with prompt tocilizumab and corticosteroid therapy.
04
Neurotoxicity monitoring with daily neurologic assessment and prompt corticosteroid intervention.
05
Comprehensive supportive care including growth factor support, infection prophylaxis, immunoglobulin replacement, transfusion support and multidisciplinary team approach with hematology, intensive care, infectious disease and neurology optimizes outcomes with this transformative cellular therapy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.